ERIS LIFESCIENCES Latest Share Price (ERIS)
TODAY IN ONE LINE
ERIS is little changed at ₹1355.50 on light volume — a quiet consolidation day, supported by recent strong earnings.
With a market cap of ₹18,777.39 Cr., it trades at a P/E of 28.98. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ERIS LIFESCIENCES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 200.0% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 96.7% and Profit up 196.7%
- ●Healthy Operating MarginsOPM is structurally strong at 29.7%
- ●High Promoter HoldingPromoters hold 54.1% skin-in-the-game
- ●Promoter BuyingPromoters increased holdings by 54.14% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 7.6%
Latest ERIS LIFESCIENCES News
What changed recently?
Recent events, corporate actions, and announcements.
ERIS LIFESCIENCES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ERIS LIFESCIENCES, framed against the sector median so the premium or discount is obvious at a glance.
ERIS LIFESCIENCES trades at a P/E of 28.98× and P/B of 4.81×, against the Healthcare sector median P/E of 46.02×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ERIS LIFESCIENCES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ERIS LIFESCIENCES — derived from the latest tape, not yesterday's close.
ERIS LIFESCIENCES last traded at ₹1,355.5 with an intraday range of ₹1,335.1–₹1,362 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1355.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1420.43 | +64.93 | +4.79% |
| R3 | 1393.53 | +38.03 | +2.81% |
| R2 | 1377.77 | +22.27 | +1.64% |
| R1 | 1366.63 | +11.13 | +0.82% |
| PIVOT | 1350.87 | -4.63 | -0.34% |
| CURRENT | 1355.50 | — | — |
| S1 | 1339.73 | -15.77 | -1.16% |
| S2 | 1323.97 | -31.53 | -2.33% |
| S3 | 1312.83 | -42.67 | -3.15% |
| S4 | 1285.93 | -69.57 | -5.13% |
ERIS is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹1335.1–₹1358
Trading Inside opening range
ERIS LIFESCIENCES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ERIS LIFESCIENCES — consolidated or standalone — with margins, YoY growth and key ratios inline.
ERIS LIFESCIENCES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹18,777.39 Cr. and reported EPS of ₹10.28.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,894 | 3,129 ▲ 8.1% |
| Sales Growth YoY %Derived | 44.02% | 8.15% |
| Other Income | 18 | 8 ▼ 57.8% |
| Total Income | 2,912 | 3,137 ▲ 7.7% |
| 714 | 796 ▲ 11.4% | |
| Gross ProfitDerived | 2,180 | 2,334 ▲ 7.1% |
| Gross Margin %Derived | 75.33% | 74.58% |
| 1,162 | 1,214 ▲ 4.4% | |
| EBITDA (Operating Profit)Derived | 1,017 | 1,120 ▲ 10.1% |
| OPM %Derived | 35.15% | 35.79% |
| 547 | 455 ▼ 16.8% | |
| Profit Before Tax (PBT) | 489 | 638 ▲ 30.6% |
| 114 | -9 ▼ 107.9% | |
| Effective Tax %Derived | 23.36% | -1.40% |
| Total Profit for Period | 375 | 648 ▲ 72.8% |
| Less: Non-controlling Interests | 23 | 28 ▲ 22.6% |
| Net Profit (Owner's PAT)Derived | 352 | 620 ▲ 76.1% |
| Net Profit Margin %Derived | 12.16% | 19.80% |
| PAT Growth YoY %Derived | -10.24% | 76.08% |
| Earnings Per Share (EPS ₹) | 25.84 | 44.72 ▲ 73.1% |
| Diluted Shares Outstanding (Cr) | 14 | 14 ▲ 1.7% |
| Share of Profit from Associates/JVs | 0 | 0 ▲ 50.0% |
| Other Comprehensive Income (Net of Tax) | -3 | -1 ▲ 56.2% |
| Total Expenses (incl. D&A & Interest) | 2,423 | 2,499 ▲ 3.1% |
| Material Cost % of RevenueDerived | 9.55% | 10.44% |
| Employee Cost % of RevenueDerived | 17.46% | 17.79% |
| Other Cost % of RevenueDerived | 22.72% | 20.99% |
| Interest Coverage (x)Derived | 3.03x | 4.36x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 856 | 982 ▲ 14.8% | 1,074 ▲ 9.4% | 1,212 ▲ 12.8% | 1,347 ▲ 11.2% | 1,685 ▲ 25.1% | 2,009 ▲ 19.2% | 2,894 ▲ 44.0% | 3,129 ▲ 8.1% | |
| Sales Growth YoY %Derived | — | 14.79% | 9.36% | 12.83% | 11.15% | 25.10% | 19.23% | 44.02% | 8.15% | |
| Other Income | 26 | 32 ▲ 20.0% | 15 ▼ 51.4% | 9 ▼ 43.4% | 26 ▲ 199.7% | 11 ▼ 57.3% | 24 ▲ 113.5% | 18 ▼ 22.9% | 8 ▼ 57.8% | |
| Total Income | 882 | 1,014 ▲ 14.9% | 1,089 ▲ 7.5% | 1,221 ▲ 12.0% | 1,373 ▲ 12.5% | 1,696 ▲ 23.5% | 2,033 ▲ 19.8% | 2,912 ▲ 43.2% | 3,137 ▲ 7.7% | |
134 | 154 ▲ 14.6% | 172 ▲ 11.6% | 238 ▲ 38.9% | 259 ▲ 8.5% | 352 ▲ 36.3% | 380 ▲ 7.9% | 714 ▲ 87.9% | 796 ▲ 11.4% | ||
| Gross ProfitDerived | 722 | 828 ▲ 14.8% | 903 ▲ 8.9% | 974 ▲ 7.9% | 1,089 ▲ 11.8% | 1,333 ▲ 22.4% | 1,629 ▲ 22.2% | 2,180 ▲ 33.8% | 2,334 ▲ 7.1% | |
| Gross Margin %Derived | 84.33% | 84.35% | 84.03% | 80.34% | 80.81% | 79.09% | 81.08% | 75.33% | 74.58% | |
400 | 484 ▲ 21.0% | 534 ▲ 10.5% | 543 ▲ 1.7% | 604 ▲ 11.2% | 796 ▲ 31.9% | 954 ▲ 19.9% | 1,162 ▲ 21.8% | 1,214 ▲ 4.4% | ||
| EBITDA (Operating Profit)Derived | 322 | 345 ▲ 7.1% | 368 ▲ 6.8% | 431 ▲ 16.9% | 485 ▲ 12.6% | 537 ▲ 10.7% | 675 ▲ 25.7% | 1,017 ▲ 50.7% | 1,120 ▲ 10.1% | |
| OPM %Derived | 37.64% | 35.12% | 34.30% | 35.53% | 36.00% | 31.85% | 33.59% | 35.15% | 35.79% | |
36 | 59 ▲ 63.7% | 52 ▼ 11.5% | 45 ▼ 14.6% | 69 ▲ 53.7% | 143 ▲ 108.1% | 267 ▲ 86.7% | 547 ▲ 104.5% | 455 ▼ 16.8% | ||
| Profit Before Tax (PBT) | 312 | 317 ▲ 1.6% | 331 ▲ 4.4% | 394 ▲ 19.1% | 442 ▲ 12.1% | 405 ▼ 8.5% | 431 ▲ 6.6% | 489 ▲ 13.4% | 638 ▲ 30.6% | |
17 | 26 ▲ 51.9% | 35 ▲ 32.9% | 39 ▲ 13.0% | 36 ▼ 7.5% | 30 ▼ 16.3% | 34 ▲ 12.1% | 114 ▲ 234.1% | -9 ▼ 107.9% | ||
| Effective Tax %Derived | 5.53% | 8.26% | 10.52% | 9.98% | 8.23% | 7.53% | 7.93% | 23.36% | -1.40% | |
| Total Profit for Period | 295 | 291 ▼ 1.3% | 297 ▲ 1.8% | 355 ▲ 19.8% | 406 ▲ 14.3% | 374 ▼ 7.8% | 397 ▲ 6.1% | 375 ▼ 5.6% | 648 ▲ 72.8% | |
| Less: Non-controlling Interests | 1 | 0 ▼ 59.8% | — ▼ 100.0% | — | -0 | -8 ▼ 2368.5% | 5 ▲ 163.4% | 23 ▲ 350.2% | 28 ▲ 22.6% | |
| Net Profit (Owner's PAT)Derived | 294 | 291 ▼ 1.1% | 297 ▲ 2.0% | 355 ▲ 19.8% | 406 ▲ 14.4% | 382 ▼ 5.9% | 392 ▲ 2.6% | 352 ▼ 10.2% | 620 ▲ 76.1% | |
| Net Profit Margin %Derived | 34.37% | 29.61% | 27.61% | 29.30% | 30.15% | 22.68% | 19.51% | 12.16% | 19.80% | |
| PAT Growth YoY %Derived | — | -1.13% | 1.96% | 19.77% | 14.35% | -5.90% | 2.57% | -10.24% | 76.08% | |
| Earnings Per Share (EPS ₹) | 21.39 | 21.15 ▼ 1.1% | 21.84 ▲ 3.3% | 26.16 ▲ 19.8% | 29.88 ▲ 14.2% | 28.10 ▼ 6.0% | 28.82 ▲ 2.6% | 25.84 ▼ 10.3% | 44.72 ▲ 73.1% | |
| Diluted Shares Outstanding (Cr) | 14 | 14 ▲ 0.0% | 14 ▼ 1.3% | 14 ▲ 0.0% | 14 ▲ 0.1% | 14 ▲ 0.0% | 14 ▲ 0.0% | 14 ▲ 0.1% | 14 ▲ 1.7% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | — | — | 0 | 0 ▲ 50.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 271.2% | -1 ▼ 977.9% | -1 ▼ 22.2% | -1 ▲ 34.0% | 0 ▲ 106.0% | -3 ▼ 5271.2% | -3 ▼ 7.8% | -1 ▲ 56.2% | |
| Total Expenses (incl. D&A & Interest) | 570 | 696 ▲ 22.2% | 758 ▲ 8.8% | 826 ▲ 9.0% | 931 ▲ 12.7% | 1,292 ▲ 38.7% | 1,602 ▲ 24.0% | 2,423 ▲ 51.3% | 2,499 ▲ 3.1% | |
| Material Cost % of RevenueDerived | 5.50% | 5.92% | 7.16% | 8.20% | 8.73% | 8.44% | 8.85% | 9.55% | 10.44% | |
| Employee Cost % of RevenueDerived | 18.39% | 19.41% | 19.15% | 18.92% | 18.73% | 20.54% | 20.10% | 17.46% | 17.79% | |
| Other Cost % of RevenueDerived | 28.31% | 29.82% | 30.58% | 25.89% | 26.08% | 26.70% | 27.40% | 22.72% | 20.99% | |
| Interest Coverage (x)Derived | 28.09x | 13.48x | 147.14x | 215.09x | 101.36x | 16.04x | 5.80x | 3.03x | 4.36x |
ERIS LIFESCIENCES segment analysis : revenue and profit mix.
Disclosed business segments at ERIS LIFESCIENCES with their share of revenue and profit, switchable between consolidated and standalone reporting.
ERIS LIFESCIENCES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ERIS LIFESCIENCES.
Our AI distills the core fundamental drivers supporting ERIS LIFESCIENCES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ERIS LIFESCIENCES's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 201.3% YoY, demonstrating exceptional earnings momentum.
Operating margin 26.56% latest quarter significantly exceeds peer average benchmarks.
Net profit margin 19.89% TTM demonstrates strong cost control and pricing power.
Promoter holding 54.14% signals strong management commitment and long-term alignment.
ROE 18.07% RFY indicates robust returns on shareholder capital deployed effectively.
Key Risks.
P/E ratio 32.09x trades above sector median, signals potential overvaluation concerns.
ROCE 13.51% lags peer benchmarks significantly, suggesting capital efficiency gaps.
Dividend yield 1.09% remains low, limiting appeal to income-focused investors.
FII holdings eased from 15.35% to 8.01%, signals foreign investor caution.
Current ratio 0.60 signals liquidity stress; working capital deficit evident.
Flip Conditions.
Valuation risk. a P/E above 38 (~0.8× the sector multiple of 46.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.15. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
ERIS LIFESCIENCES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ERIS LIFESCIENCES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ERIS LIFESCIENCES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ERIS LIFESCIENCES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ERIS LIFESCIENCES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ERIS LIFESCIENCES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ERIS LIFESCIENCES stood at 48.2% of traded volume, against a 20-day average of 55.9%.
ERIS LIFESCIENCES announcements: results, concalls, ratings, M&A.
Filings ERIS LIFESCIENCES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ERIS LIFESCIENCES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 170 documents below.
Resignation
Eris Lifesciences Limited has informed the Exchange regarding Resignation of Mr Krishnakumar Vaidyanathan as Executive Director of the company w.e.f.…
Rumour Verification - Regulation 30(11)
Eris Lifesciences Limited has informed the Exchange about Rumour Verification - Regulation 30(11)
Agreements
Eris Lifesciences Limited has informed the Exchange about Loan Agreement
Analysts/Institutional Investor Meet/Con. Call Updates
Eris Lifesciences Limited has informed the Exchange about Schedule of meet
Copy of Newspaper Publication
Eris Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
ERIS LIFESCIENCES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ERIS LIFESCIENCES has declared, sequenced by announce and record date.
ERIS LIFESCIENCES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ERIS LIFESCIENCES: business, sector, key facts.
What ERIS LIFESCIENCES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ERIS LIFESCIENCES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ERIS, BSE: 540596.
Eris Lifesciences Limited is a pharmaceutical company headquartered in Ahmedabad, India, that focuses on providing domestically branded formulations for chronic and sub-chronic therapeutic treatments within the Indian market. Their business model centers on developing and marketing a wide range of branded medications across several key therapeutic areas.
The company's product portfolio covers a diverse spectrum of medical needs. This includes treatments for anti-diabetes, cardiovascular diseases, dermatological conditions, neurological disorders, gynecological issues, nephrological problems, and oncology. Additionally, they offer products focused on central nervous system health, women's health, and nutritional supplements like vitamins and minerals.
Beyond just medication, Eris Lifesciences also provides various patient care services to enhance healthcare access and management. These services include ambulatory blood pressure and electrocardiogram monitoring, continuous glucose monitoring, sleep studies, and antenatal care solutions. This integrated approach differentiates them in the market by offering a more holistic patient experience.
Eris Lifesciences distributes its products through a well-established network encompassing wholesale drug distributors, stockists, and retail pharmacies, ensuring wide accessibility across India. This robust distribution network is a key component of their strategy for reaching a broad patient base and maintaining market presence.
Founded in 2007, Eris Lifesciences has built a significant presence in the Indian pharmaceutical market through its commitment to providing affordable and effective medications combined with supportive patient care services. Their focus on chronic and sub-chronic therapies signifies a dedication to addressing the long-term health needs of a considerable segment of the population.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ERIS LIFESCIENCES (ERIS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ERIS LIFESCIENCES (ERIS)?
The current share price of ERIS LIFESCIENCES (ERIS) is ₹1,355.50. Today, the stock has declined by ₹1.10 (0.08%), trading in a range of ₹1,335.10 to ₹1,362.00. The stock opened at ₹1,356.60 with a trading volume of 24,968 shares.
02Is ERIS LIFESCIENCES stock a good investment for long-term?
ERIS LIFESCIENCES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹18,777.39 Cr., P/E ratio of 28.98, ROE of 7.64%, and ROCE of 6.96%. The dividend yield stands at 0.53%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ERIS LIFESCIENCES stock?
The 52-week high price of ERIS LIFESCIENCES (ERIS) is ₹1,740.00, while the 52-week low is ₹1,200.00. Currently trading at ₹1,355.50, the stock is 12.96% above its 52-week low and 22.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ERIS LIFESCIENCES stock at the current price?
Whether to buy ERIS LIFESCIENCES stock at ₹1,355.50 depends on multiple factors. The stock is currently trading with a P/E ratio of 28.98 and P/B ratio of 4.81. Today's performance shows a loss of 0.08%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ERIS LIFESCIENCES and when is the next dividend?
ERIS LIFESCIENCES offers a dividend yield of 0.53%, which means for every ₹100 invested at the current price of ₹1,355.50, you can expect to receive approximately ₹0.53 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ERIS LIFESCIENCES?
ERIS LIFESCIENCES's key financial metrics include: P/E Ratio: 28.98, P/B Ratio: 4.81, ROE: 7.64%, ROCE: 6.96%, Dividend Yield: 0.53%, EPS: ₹10.28, Book Value: ₹281.12, and Debt-to-Equity: 0.65. The company's market cap stands at ₹18,777.39 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ERIS LIFESCIENCES stock performing today in the market?
ERIS LIFESCIENCES stock opened at ₹1,356.60 and is currently trading at ₹1,355.50, showing a decline of ₹1.10 (0.08%). The intraday high is ₹1,362.00 and low is ₹1,335.10. The trading volume stands at 24,968 shares, indicating moderate market participation today.
08What is the P/E ratio of ERIS LIFESCIENCES and what does it indicate?
ERIS LIFESCIENCES has a Price-to-Earnings (P/E) ratio of 28.98, which means investors are willing to pay 28.98 for every ₹1 of earnings. With an EPS of ₹10.28, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ERIS LIFESCIENCES (ERIS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.